Targeting B cell Activation driven by Natural Killer cells
One of 10,000+ projects Taiyo tracks in France.
Source: EU Funding & Tenders Portal
Autoimmune diseases affect nearly 4% of the world’s population and can be life-threatening. Among them, primary Sjögren Syndrome (pSS) is the most common systemic autoimmune disease. Unfortunately, to date, treatments are focusing on relieving symptoms. It is of public relevance to find potential new biomarkers for treatments. B cells are one key player in pSS and promising drugs targeting B cell
- Status
- Closed
- Sector
- Education
- Location
- France
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Targeting B cell Activation driven by Natural Killer cells
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Autoimmune diseases affect nearly 4% of the world’s population and can be life-threatening. Among them, primary Sjögren Syndrome (pSS) is the most common systemic autoimmune disease. Unfortunately, to date, treatments are focusing on relieving symptoms. It is of public relevance to find potential new biomarkers for treatments. B cells are one key player in pSS and promising drugs targeting B cell activation are currently under phase 3 clinical trials. Restraining B cell hyperactivity is central to treating pSS permanently. Hence, instead of targeting B cell activation, pSS treatments would also benefit from targeting signals or interactions leading to B cell activation. The TABANK project aims to address this hypothesis by using cutting-edge technologies (high-parameter flow cytometry, single-cell sequencing technologies and unsupervised analysis) to interrogate the immune network in the circulation of pSS donors as well as in the inflamed environment of impaired salivary glands. This overarching goal will be achieved by (i) Compiling a comprehensive database of immune cell profiles in pSS using both single-cell sequencing and high-parameter mass and flow cytometry; (ii) Determining potential interactions of immune cells leading to B cell activation using a novel computational approach; and (iii) Validating these interactions using ex vivo culture. TABANK will be conducted at the Lymphocytes B, Autoimmunity and Immunotherapies center, Université of Brest Occidentale a leading research institution in the study of immunotherapies for B cell diseases. This project will be supervised by two leading experts in autoimmune diseases and B cell biology. This unique synergy, in addition the researcher’s own expertise in examining immune responses in human tissues, particularly oral mucosal tissues, will precondition the project for success while facilitating a mutually beneficial, two-way transfer of knowledge. |
Location
Country | France |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Education |
Article published date | 2025-10-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
